The overall goal of the Clinical Core is to provide University of Kansas (KU) Alzheimer's Disease Core Center (ADCC) investigators with access to a well-characterized cohort of research participants with and without dementia. The Clinical Core will continue to emphasize recruiting nondemented individuals and those in the earliest symptomatic stages of AD, including mild cognitive impairment (MCI). This overall goal will be met by the following specific aims:
Aim 1. Maintain an active cohort of nondemented, mild cognitive impairment (MCI) and AD subjects to support cross-sectional and longitudinal studies.
Aim 2. Support and encourage collaborative interdisciplinary studies on AD and aging by providing data, biological specimens, and clinical research infrastructure, expertise and support to approved investigators and national data sharing initiatives (i.e., NACC). The initiation of the Clinical Core in 2004 (previously known as the Alzheimer and Memory Program) has stimulated the growth of AD and aging research at KU. In six years, the program has significantly broadened the base of AD investigators by stimulating collaborative studies, providing a training environment for the next generation of AD investigators, and by attracting new faculty to the campus. The Clinical Core has developed essential infrastructure and participant recruitment capabilities that directly supports the research efforts of faculty members in the Schools of Medicine, Allied Health, and Nursing. The research and training foundation of the Clinical Core will provide KU investigators with the infrastructure to build on this history and pursue the novel role of metabolic dysfunction in neurodegeneration and aging.
With the aging population, age-related disorders such as dementia are rising in prevalence at an unprecedented rate. Prompting and supporting clinical and translational research into neurodegenerative disorders may lead to important prevention and treatment strategies.
|Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211|
|Menta, Blaise W; Swerdlow, Russell H (2018) An Integrative Overview of Non-Amyloid and Non-Tau Pathologies in Alzheimer's Disease. Neurochem Res :|
|Deng, Yue; Jiang, Beichen; Rankin, Carolyn L et al. (2018) Methionine sulfoxide reductase A (MsrA) mediates the ubiquitination of 14-3-3 protein isotypes in brain. Free Radic Biol Med 129:600-607|
|Ptomey, Lauren T; Szabo, Amanda N; Willis, Erik A et al. (2018) Remote Exercise for Adults with Down Syndrome. Transl J Am Coll Sports Med 3:60-65|
|Qian, Winnie; Fischer, Corinne E; Schweizer, Tom A et al. (2018) Association Between Psychosis Phenotype and APOE Genotype on the Clinical Profiles of Alzheimer's Disease. Curr Alzheimer Res 15:187-194|
|Perales, Jaime; Hinton, Ladson; Burns, Jeffrey et al. (2018) Cardiovascular health and cognitive function among Mexican older adults: cross-sectional results from the WHO Study on Global Ageing and Adult Health. Int Psychogeriatr 30:1827-1836|
|Gallagher, Damien; Kiss, Alex; Lanctot, Krista et al. (2018) Depression and Risk of Alzheimer Dementia: A Longitudinal Analysis to Determine Predictors of Increased Risk among Older Adults with Depression. Am J Geriatr Psychiatry 26:819-827|
|Perales, Jaime; Moore, W Todd; Fernandez, Cielo et al. (2018) Feasibility of an Alzheimer's disease knowledge intervention in the Latino community. Ethn Health :1-12|
|Haaksma, Miriam L; Calderón-Larrañaga, Amaia; Olde Rikkert, Marcel G M et al. (2018) Cognitive and functional progression in Alzheimer disease: A prediction model of latent classes. Int J Geriatr Psychiatry 33:1057-1064|
|Gupta, Aditi; Thomas, Tashra S; Klein, Jeffrey A et al. (2018) Discrepancies between Perceived and Measured Cognition in Kidney Transplant Recipients: Implications for Clinical Management. Nephron 138:22-28|
Showing the most recent 10 out of 333 publications